Icagen and Omdana Therapeutics Announce Collaboration to Pursue Therapies for Patients with Pulmonary Hypertension
Wednesday, June 21, 2017
Icagen, Inc. and Omdana Therapeutics, Inc. announced a collaboration to help advance the discovery of novel medicines for disorders related to tissue homeostasis and vascular remodeling such as pulmonary hypertension. Omdana, a company co-founded by pharma veterans Drs. Christopher VanDeusen and Steve Ledbetter, will partner with Icagen as an integrated drug discovery team with the goal of developing high-quality, advanced leads ready for clinical trials.
"Omdana is venturing into this program because therapies are needed that can truly address underlying tissue and vascular remodeling," said Dr. VanDeusen. "Icagen represents an ideal partner for moving from target to lead in a timely manner. Icagen's scientific team and their breadth of experience and capabilities are second to none."
"Icagen is pleased to partner with Omdana Therapeutics on this important project," said Richie Cunningham, President & CEO of Icagen. "The Omdana co-founders also bring years of pharma experience and know-how for making successful drug candidates. Together we believe that we can make a nimble team of drug discoverers ready to advance compounds at a pace that we expect will beat the industry average."
